Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.
暂无分享,去创建一个
H. Scher | M. Galsky | M. Eisenberger | S. Slovin | W. Kelly | Yih Lee | W. Kelly | A. Delacruz | I. Webb | S. Moore-Cooper
[1] H. Scher,et al. Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Simon A. Williams,et al. Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human , 2006, The Prostate.
[3] R. Lutz,et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. , 2006, Cancer research.
[4] T. Chittenden,et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. , 2006, Cancer research.
[5] S. Larson,et al. Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer , 2005, Clinical Cancer Research.
[6] Anna M Wu,et al. Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.
[7] M. Silva,et al. A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody–Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer , 2004, Cancer Research.
[8] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[9] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[10] S. Vallabhajosula,et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] A. Tolcher,et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] S. Cingarlini,et al. Anti‐tumor effects of toxins targeted to the prostate specific membrane antigen , 2002, The Prostate.
[13] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[14] B. Freidlin,et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] D. Bostwick,et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. , 1998, Urology.
[16] N. Bander,et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. , 1998, Cancer research.
[17] R Simon,et al. Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.
[18] P. Schellhammer,et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.
[19] George L. Wright,et al. Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids , 1995, International journal of cancer.
[20] W. Fair,et al. Expression of the prostate-specific membrane antigen. , 1994, Cancer research.
[21] C. Cordon-Cardo,et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] S. Shah,et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. , 1992, Cancer research.